Curis signs agreement for emavusertib/pembrolizumab combination melanoma study

Curis (CRIS) has entered into an investigator-initiated clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma. Curis is responsible for supply of emavusertib, Merck (MRK) is responsible for supply of pembrolizumab and clinical study costs. Both companies retain 100% of the commercial rights to their respective programs. The study is expected to begin enrollment in first half 2024.